What are the requirements for clinical trial liability insurance?

The most common misunderstanding is that a government agency sets one clinical trial insurance requirement. It does not. The requirement to carry clinical trial liability insurance comes from whichever of three parties has leverage over the trial: the sponsor, the host institution, and (in many countries) the national regulator. A trial usually has to satisfy all three at once, and the strictest of them sets the effective bar.

That is why two trials of the same molecule can face very different insurance requirements - a single-site US Phase 1 governed only by a CTA and an institutional IRB looks nothing like a multi-country Phase 3 that also has to meet EU Clinical Trials Regulation 536/2014.

The sponsor imposes the most detailed requirements through the clinical trial agreement (CTA) or the master services agreement with a CRO. These typically specify a required clinical trial liability limit, additional-insured status for the sponsor, indemnification of the sponsor for third-party subject-injury claims, primary and non-contributory wording, waiver of subrogation, and a defined notice-of-cancellation period. Where a CRO is running the trial, the sponsor MSA pushes matching requirements down to the CRO and often to the sites.

These are contract terms, not statutes, so they are negotiable - but the sponsor holds the leverage, and the schedule in the CTA is usually where the real, enforceable insurance requirement lives for a US trial.

The research institution and its IRB set their own condition-of-hosting requirements, which frequently include evidence of clinical trial / subject-injury coverage and a defined approach to compensating a subject harmed by trial participation. Human-subject protection under the Common Rule (45 CFR 46) and FDA IND regulations (21 CFR 312) govern how injury and its handling are disclosed in the informed-consent process, which in turn shapes what coverage the institution expects to see.

Outside the US, regulators mandate coverage directly. EU Clinical Trials Regulation 536/2014 requires, through its Article 76 provisions, that a system (insurance, a guarantee, or a national indemnity scheme) be in place to compensate subjects for trial-related damage - a hard legal requirement, not a contract term. Other jurisdictions have their own mandates. ICH-GCP, the international standard, expects the sponsor to provide for subject-injury compensation consistent with applicable regulation, which is why globally-run trials default to carrying the coverage even where a specific country does not compel it.

Required limits scale with trial phase, the number and location of sites, enrollment, and the indication. Market-typical requirements run from roughly $5M-$10M for an early-phase, single-country study up to $10M-$25M or more for a large multi-country Phase 3, with higher-risk indications and vulnerable populations pushing the required limit up. EU and other ex-US sites frequently drive both higher limits and country-specific policy features to satisfy local mandates.

Beyond the limit, the recurring required terms are additional-insured status for the sponsor and institution, indemnification consistent with the CTA, no-fault subject-injury compensation where the jurisdiction or institution expects it, and a claims-made or occurrence form appropriate to the trial's duration and the long tail of injury claims. Because the requirements come from multiple parties, the placement has to be built to satisfy the strictest combination, not any one of them alone.